Researchers at Bristol University have created a lay summary for their research. The project will investigate the mechanisms of a new clinical drug combination currently in clinical trials for breast ...
Combining statins with another drug, ezetimibe, significantly reduces the risk of death in patients with clogged arteries, ...
News-Medical.Net on MSN5h
Blocking an enzyme to overcome immunotherapy resistance in melanoma patientsAbout 65% of melanoma patients do not respond to immunotherapy. New work by the team of Prof. Max Mazzone (VIB-KU Leuven ...
SON-1010 is being studied as a combination therapy with trabectedin (Yondelis®), the first FDA-approved treatment for two types of advanced soft ...
Epsilogen completes acquisition of TigaTx to create world’s leading pan-isotype cancer antibody company: London Tuesday, April 8, 2025, 10:00 Hrs [IST] Epsilogen, the global lea ...
About 65% of melanoma patients do not respond to immunotherapy. New work by the team of Prof. Max Mazzone (VIB-KU Leuven ...
President Trump's sweeping tariff and policy shifts could undermine plans to expand U.S. production of critical minerals for ...
The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced ...
Scientists discovered Earth's first crust had continental chemical signatures. This challenges beliefs about when these ...
Oral presentation on April 13, 2025, highlighting positive BV100 Phase 2 VABP trial read-out with excellent efficacy and safety data Complementary poster presentations featuring clinical & preclinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback